Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTI-CENTER STUDY to EVALUATE the SAFETY and EFFICACY of SUBCUTANEOUS MANP WHEN ADMINISTERED ONCE DAILY for 42 DAYS in PARTICIPANTS with DIFFICULT to CONTROL HYPERTENSION/RESISTANT HYPERTENSION

X
Trial Profile

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTI-CENTER STUDY to EVALUATE the SAFETY and EFFICACY of SUBCUTANEOUS MANP WHEN ADMINISTERED ONCE DAILY for 42 DAYS in PARTICIPANTS with DIFFICULT to CONTROL HYPERTENSION/RESISTANT HYPERTENSION

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs M atrial natriuretic peptide (Primary)
  • Indications Resistant hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BOLD-HTN
  • Sponsors E-Star BioTech
  • Most Recent Events

    • 12 Oct 2024 New trial record
    • 08 Oct 2024 According to an E-Star BioTech media release, the company is currently preparing to enroll their first patient in this trial.
    • 08 Oct 2024 According to an E-Star BioTech media release, company announced that it is set to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension (BOLD-HTN) supported by a recent round of financing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top